Belzutifan Generates ‘Excitement’ in Renal Cell Carcinoma, Expert Says

Video

Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.

At the 2023 Kidney Cancer Research Summit (KCRS), CancerNetwork® spoke with Rana R. McKay, MD, about in the potential of angiogenic agents patients with renal cell carcinoma (RCC), including HIF-2α inhibitor belzutifan (Welireg).1

McKay, a board-certified medical oncologist and associate professor in the Department of Medicine at University of California, San Diego Health, highlighted the excitement surrounding the role belzutifan, which was previously approved by the FDA previously approved belzutifan in von Hippel-Lindau (VHL) disease,2 may play in treating those with RCC as the agent continues to be assessed across the first-line, refractory, and adjuvant settings.

Moreover, she highlighted that several other anti-angiogenesis agents are under investigation in this patient population such as VEGF/MET inhibitor XL092.

Transcript:

The non-immunotherapy-based treatment strategies continue to [include] targeting anti-angiogenic access. One of the “next kids on the block,” if you will, is a drug called belzutifan. It’s HIF-2α inhibitor that has been under development for quite some time. It actually is already FDA-approved for the treatment of VHL disease,2 and is certainly under investigation for sporadic renal cell carcinoma. There’s a lot of excitement around belzutifan; it’s being tested in the refractory setting, in the frontline setting, even in the adjuvant setting. It’s going to be interesting to see where that agent ends up panning out in RCC. And there are other HIF-2α inhibitors that are also under development. It’ll be interesting to see how they all compete with a drug like belzutifan.

Other angiogenic agents include XL092, which is a VEGF/MET inhibitor that has properties similar to cabozantinib but pharmacokinetically, it’s a little bit different: it has a shorter half-life, and is given once daily. There are several trials that are investigating that agent. There are other mechanisms of actually being able to target HIF beyond a small molecule inhibitor that are also undergoing testing, but there’s further refinement that is needed.

References

  1. McKay RR. Novel Therapies. Presented at: 2023 Kidney Cancer Research Summit; July 13-14, 2023; Boston, MA.
  2. FDA approves belzutifan for cancers associated with von Hippel-Lindau disease. News release. FDA. August 13, 2021. Accessed July 17, 2023. https://bit.ly/37DMnzV

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Related Content